{"title": "Opzelura - European Medicines Agency", "author": "EMA; COMM; DG; UNIT", "url": "https://www.ema.europa.eu/en/medicines/human/EPAR/opzelura", "hostname": "europa.eu", "description": "Opzelura", "sitename": "European Medicines Agency", "date": "2023-02-22", "cleaned_text": "is a medicine used for treating non-segmental vitiligo, a disease that causes patches of skin to lose colour on both sides of the body. In patients with vitiligo, the immune system (the body's natural defences) attacks melanocytes (the skin cells that make pigment), causing patches of pale pink or white skin (depigmentation). Opzelura is used in adults and adolescents from 12 years of age with non-segmental vitiligo that also affects the face. Opzelura contains the [active substance](/en/glossary/active-substance) ruxolitinib. - List item Opzelura overview (PDF/119.97 KB) First published: 20/04/2023 EMA/100444/2023 - - List item Opzelura : EPAR - Risk management plan summary | 1 |Date of issue of marketing authorisation valid throughout the European Union|| | 19/04/2023 |Contact IB/0001/G This medicine's [product information](/en/glossary/product-information) available in all official EU languages. Select 'available languages' to access the language you need. [Product information](/en/glossary/product-information) contain: [summary of product characteristics](/en/glossary/summary-product-characteristics)(annex I); - manufacturing authorisation holder responsible for batch release (annex IIA); - documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the [Veterinary Medicines Information website](https://www.medicinesinfo.eu/). Pharmacotherapeutic group Other dermatological preparations Therapeutic indication Opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. "}